Nesiritide, a recombinant human B-type natriuretic peptide, is the first in a new drug class for the treatment of decompensated heart failure. The drug binds to receptors in the vasculature, kidney, adrenal gland, and brain, and overcomes resistance to endogenous BNP present in patients with ...
Drug ClassCardiovasculars; Natriuretic peptides, type-B human IndicationsAcute CHF MechanismStimulates cGMP production and thus vascular smooth muscle relaxation Dosage With QualifiersAcute CHF—begin 2mcg/kg IV bolus, then 0.01mcg/kg/min IV; decrease or discontinue if hypotension; max 0.03mcg/kg/min...
Nesiritide: a new drug for the treatment of decompensated heart failure. Nesiritide, a recombinant human B-type natriuretic peptide, is the first in a new drug class for the treatment of decompensated heart failure. The drug bin... U Elkayam,MW Akhter,P Tummala,... - 《Journal of Cardiovas...
Recent meta-analyses of existing databases have raised concerns regarding adverse effects of the drug on 30-day mortality. However, reviews of large, observational, registry databases do not suggest an adverse inpatient mortality effect compared with other vasodilator therapies. Further resolution of the...
The article presents several questions and answers related to nesiritide, the first drug in a new class for treating heart failure. In reply to a question related to the working of nesiritide, it is stated that it helps relax vascular smooth muscle, dilating veins and arteries. In reply to ...
Nesiritide (human B-type natriuretic peptide) is a promising new class of drugs that has been given to almost 1,000 patients in numerous clinical investigations. The clinical development of nesiritide included dosing studies (utilizing repetitive boluses, continuous infusions, or a combination of ...
CONCLUSION: Nesiritide represents the first drug in a new class designed for treatment of ADHF. In patients with ADHF, nesiritide improves hemodynamic parameters and reduces dyspnea. Questions remain about possible increased mortality and side effects. A continuing study expected to enroll 7000 patients...
Nesiritide: a new drug for the treatment of decompensated heart failure. Nesiritide, a recombinant human B-type natriuretic peptide, is the first in a new drug class for the treatment of decompensated heart failure. The drug bin... Uri,Elkayam,M Waseem,... - 《Journal of Cardiovascular Pharm...
dL should receive drug therapy with a goal of reducing LDL-C levels to <100 mg/dL. The recent results of the United Kingdom's Heart Protection Study (HPS) strongly suggest that even those with CAD or who are at high risk and LDL-C levels >100 mg/dL would benefit from drug therapy....
Rosuvastatin, which is in the later stages of the US Food and Drug Administration (FDA) approval process, has been shown to produce significantly greater reductions in LDL-C levels compared with atorvastatin, simvastatin, and pravastatin, and allows more patients to meet lipid goals. Ezetimibe, ...